Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement

Ajinomoto will support fill finish for investigational COVID-19 therapeutic, lenzilumab, nearing completion of phase 3 study.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, and Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is one of the few Phase 3 treatment options in development for patients hospitalized with COVID-19. 
 
Aji Bio-Pharma will assume a key role in simplifying the supply chain efforts for Humanigen by providing drug product aseptic fill finish services at its San Diego facility to support continued clinical trial efforts through potential commercialization. Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization (EUA) for lenzilumab.
 
“We are very pleased to be working with Aji Bio-Pharma for the fill finish production of lenzilumab,” said Cameron Durrant, chief executive officer, Humanigen. “This partnership allows us to utilize Aji Bio-Pharma’s high quality drug product aseptic fill finish services to provide a timely supply of lenzilumab as we near the end of our clinical phase 3 study and prepare for EUA application submission.”
 
Kristin DeFife, senior vice president of operations and site head, Ajinomoto Bio-Pharma Services, said, “We are excited to continue to support Humanigen’s efforts to provide this potential therapeutic in the fight against COVID-19. Through this collaboration, we are able to leverage our drug product experience, infrastructure and strong regulatory track record to assist in the efforts that may ultimately help patients struggling with this devastating disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics